Table 1. Patient and treatment characteristics of BNCT in HGMs.
| SBMs ( n = 9) |
Non-SBMs ( n = 24) | p | |
|---|---|---|---|
| Age at BNCT (years) | |||
| 57.1 | 58.7 | 0.77 | |
| Gender | |||
| Male | 2 | 9 | 0.68 |
| Female | 7 | 15 | |
| WHO grade | |||
| II | 3 | 9 | 0.69 |
| III | 6 | 15 | |
| T/N ratio of PET study | |||
| Mean | 4.0 | 3.7 | 0.47 |
| Number of prior surgeries (times) | |||
| Mean | 3.6 | 2.8 | 0.15 |
| Number of prior radiotherapies (times) | |||
| Mean | 1.8 | 2.1 | 0.56 |
| Minimum absorbed dose in tumor tissue (Gy-Eq) | |||
| Mean | 23.3 | 42.4 | a 0.001 |
| Maximum absorbed dose in tumor tissue (Gy-Eq) | |||
| Mean | 67.2 | 73.4 | 0.33 |
| Tumor depth (mm) | |||
| Mean | 76.1 | 49.9 | a < 0.001 |
| Number of BNCT(times) | |||
| Mean | 1.4 | 1.3 | 0.52 |
Abbreviations: BNCT, boron neutron capture therapy; tumor depth, distance from the scalp surface to the deepest part of the tumor; Gy-Eq, Gray Equivalent; HGMs, high-grade meningiomas; PET, positron emission tomography; SBMs, skull base meningiomas; T/N, the tumor-to-normal brain ratio; WHO, World Health Organization.
a
p < 0.05 was considered statistically significant.